Abstract

Inflammatory bowel diseases, mainly ulcerative colitis and Crohn’s disease are characterized by chronic inflammation in the intestine. Currently several therapeutic strategies available to treat inflammatory bowel diseases. Though, most treatments can be associated with serious adverse effects what justifies the search for new treatments. In this sense, we highlight the interest in herbal products rich in bioactive compounds which immunomodulatory and antioxidant properties as is the case of Bryophyllum pinnatum (Crassulaceae). This plant is used in traditional medicine in Brazil for treating inflammatory diseases. We hypothesized that hydroethanolic B. pinnatum leaf extract has intestinal anti-inflammatory effects on two experimental colitis models: 2.4-dinitrobenzene sulfonic acid (DNBS) in rats, and dextran sulfate sodium (DSS) in mice. Ultra-fast liquid chromatography method used for the quantification of the main compounds indicated good linearity, specificity, selectivity, precision, robustness and accuracy. The major flavonoids (mg/g of the extract) quantified were: quercetin 3-O-α-L-arabinopyranosyl-(1→2)-α-L-rhamnopyranoside (35.56 ± 0.086 mg/g), kaempferol 3-O-α-L-arabinopyranosyl-(1→2)-α-L-rhamnopyranoside (4.66 ± 0.076 mg/g) and quercetin-3-O-rhamnopyranoside (4.56 ± 0.026 mg/g). The results obtained in the DNBS and DSS models indicate that extract has both chemopreventive and anti-inflammatory effects, observing a significant reduction in the disease activity index score, and less macroscopic and microscopic damage. The extract promoted downregulation of Toll-like receptor and kappa B p65 nuclear factor gene expression, leading to a reduction in pro-inflammatory and oxidative mediators, chemokines, and cell adhesion molecules. This immunomodulatory property was proposed that one of the possible action mechanisms of extract. An improvement in intestinal damage was also associated with a reduction in oxidative stress and infiltration of leukocytes, as evidenced by the reduction in malonaldialdehyde and myeloperoxidase activity and increase in total glutathione in the colonic tissue. Moreover, the extract improved the cytoarchitecture of the colonic tissue and the integrity of the intestinal epithelial barrier by restoring the expression of the proteins associated with mucosa protection. In view of the beneficial effects showed by the B. pinnatum leaf extract in preclinical rodent models of colitis there is the potential to conduct some future clinical studies to ensure safe and effective development of a phytotherapeutic treatment for human inflammatory bowel diseases.

Highlights

  • Ulcerative colitis (UC) and Crohn’s disease (DC) are inflammatory bowel diseases (IBD) referring to chronic idiopathic diseases of the gastrointestinal tract, being characterized by chronic and recurrent inflammation of the intestine (Wu et al, 2020)

  • Most of the peaks found have already been identified and previously described by our research group (Fernandes et al, 2016), but this is the first time that the content of major flavonoids has been quantified and correlated with the pharmacological response

  • The major flavonoid, Bp1, and other two compounds B. pinnatum: kaempferol 3-O-a-L-arabinopyranosyl(1!2)-a-L-rhamnopyranoside (Bp2) and Bp3 were quantified as possible analytical markers this species

Read more

Summary

Introduction

Ulcerative colitis (UC) and Crohn’s disease (DC) are inflammatory bowel diseases (IBD) referring to chronic idiopathic diseases of the gastrointestinal tract, being characterized by chronic and recurrent inflammation of the intestine (Wu et al, 2020). Its etiology is not yet fully understood, but it is most likely related to genetic and environmental factors, changes in the composition of the intestinal microbiota and an exacerbated and abnormal immune response (Pallio et al, 2016). This altered immune response promotes an increase in inflammatory mediators responsible for generating and maintaining inflammation in IBD, including pro-inflammatory cytokines such as interleukin (IL)-1b, IL-6, IL-17, tumor necrosis factor (TNF) a, prostaglandins, and nitric oxide (NO). In IBD, chronic inflammation occurs because acute inflammatory mechanisms cannot eliminate tissue injury In this process, germline-encoded pattern-recognition receptors (PRRs) are activated in both immune and non-immune cells. The high levels of iNOS and NO released in the mucosa in IBD cause severe tissue damage and intensified inflammation (Soufli et al, 2016)

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call